PRESS RELEASE published on 09/17/2025 at 14:00, 4 months 20 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 4 months 25 days ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 4 months 25 days ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 4 months 27 days ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 4 months 27 days ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 6 months 3 days ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 6 months 8 days ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 6 months 8 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 6 months 8 days ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 6 months 8 days ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
Published on 02/07/2026 at 01:00, 1 day 4 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 6 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 7 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 13 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 15 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 8 hours 18 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 12 hours 43 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 12 hours 58 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 9 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 11 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 10 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 13 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/05/2026 at 18:06, 2 days 11 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
